Neurology
Seizure
101
Pipeline Programs↗
26
Active Trials↗
44
Companies Involved↗
Seizure is a highly competitive landscape with 101 programs across 44 companies. The most active players are Validus Pharmaceuticals, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Neurocrine Biosciences. 35 therapies are approved with 30 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 15
Phase 223
Phase 330
Analysis
Trial Status
264
clinical trials
Completed193 · 73%
Terminated32 · 12%
Recruiting18 · 7%
Withdrawn8 · 3%
Not yet recruiting6 · 2%
Unknown status4 · 2%
Other3 · 1%
Clinical Trials
Trial Activity
264 trials
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Recruiting·—·Phase 2·NCT07130786·150 enrolled
A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
Recruiting·—·Phase 4·NCT06967012·30 enrolled
Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)
Recruiting·—·Phase 4·NCT07072624·1,260 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)